MedTrace Logo

Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer

NCT03180567 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-06-08

No results posted yet for this study

Summary

As drug response is a complex trait in the majority of cases using an optimal starting dose for an individual may reduce the time taken to reach a stable INR, and reduce the risk of having either a high INR (with a risk of bleeding) or a low INR (with a risk of thrombosis)

Conditions

Interventions

DIAGNOSTIC_TEST

Genetic Mutations

By next generation sequencing

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Amr Gawaly, Consultant · Hematology Dept. - Tanta University

  • Said Hammad Abdou, Prof · Clinical Pathology dept.- Tanta University

  • Enas Abdul-Raouf, Lecturer · Biology and Genetics- Tanta University

  • Abdelaziz Zidane, Lecturer · Genetics-Damanhour University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-06
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03180567 on ClinicalTrials.gov